Volatile anesthetic sevoflurane suppresses lung cancer cells and miRNA interference in lung cancer cells
Authors Wang L, Wang T, Gu JQ, Su HB
Received 19 April 2018
Accepted for publication 25 June 2018
Published 11 September 2018 Volume 2018:11 Pages 5689—5693
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
Le Wang, Tiao Wang, Jia-Qi Gu, Hui-Bin Su
Department of Anesthesiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215000, China
Purpose: Sevoflurane is widely used in lung cancer surgery. It is well known that volatile anesthetics have a lung-protective effect in lung cancer surgery. However, the association between the inhibition of cancer cells and miRNAs interference remains unknown. Whether sevoflurane can affect some miRNAs in A549 cells has not been reported. The main aim of the present study was to investigate the effect of 3% sevoflurane on A549 cells and assess whether it regulates A549 cells by interfering with miRNA.
Methods: In three percent sevoflurane-pretreated A549 cells, treated for a duration of 30 minutes, the apoptosis rate of A549 cells was evaluated using a flow cytometer. The expression of 6 types of miRNAs associated with non-small cell lung cancer was analyzed by real-time quantitative polymerase chain reaction.
Results: An obvious apoptosis-promoting effect was found in A549 cells, which had been treated with 3% sevoflurane. The expression of several miRNAs that regulate apoptosis was significantly changed compared with the control group.
Conclusion: Three percent sevoflurane can significantly increase the apoptosis rate of A549 cells, which may reduce the spread of cancer cells caused by operation. Sevoflurane disturbed the expression of the miRNAs that regulate apoptosis.
Keywords: sevoflurane, miRNAs, apoptosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]